

MDHHS – MCIR Release Notes

Version 2023 – MCIR OLTP 2023 9.4.2.2 – RFC 216796

Release Date: April 12, 2023

Forecasting & Assessment Updates

There was a correction to COVID-19 forecasting for third dose of primary series for children ages 6 months to 4 years. (Ref. ID 2264)

- A 3-dose primary series is recommended.
 - A monovalent vaccine is administered for the first and second doses, which are separated by 3–8 weeks.
 - A bivalent vaccine is administered for the third primary series dose **at least 8 weeks** after the second monovalent primary series dose.
 - Currently, a booster dose using any COVID-19 vaccine is not authorized for children in this age group who receive a bivalent Pfizer-BioNTech vaccine for the third primary series dose.

Correct forecasting for bivalent as dose 3 at 8 weeks, 2 months, 3 months

SARS-CoV-2					
COVID-19 PFR-BNT 3mcg/0.2mL	1	3 Years 8 Months	09/01/2022	MDHHS Nurse Educators	Unknown Delete
COVID-19 PFR-BNT 3mcg/0.2mL	2	3 Years 10 Months	11/01/2022	MDHHS Nurse Educators	Unknown Delete

forecasting for third dose as bivalent - 8 weeks, 2 months, 3 months- correct

Pfizer Bivalent 3MCG PED	YES	3	12/27/2022	01/01/2023	02/01/2023
Pfizer Bivalent 3mcg Ped		3	12/27/2022	01/01/2023	02/01/2023

Updates

HL7 Viewer - This release included a technical update. Last month we began a data quality and database optimization process which temporarily removed HL7 Viewer historical display prior to March 1, 2023. Effective today, the HL7 historical data before March 1, 2023, has been restored. (Ref. #2293)

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at MDHHS-MCIRHelp@michigan.gov.